Phacilitate Leaders World

Sponsors & Exhibitors

Sangamo Therapeutics

Sangamo Therapeutics is developing novel zinc finger DNA-binding proteins (ZFPs), for therapeutic gene regulation and genome editing and has ongoing Phase 2 clinical trials to evaluate safety and efficacy of a ZFP Therapeutic® for the treatment of HIV/AIDS.    Other therapeutic programs are focused on monogenic diseases.  Sangamo engineers sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) for gene regulation. The company has an agreement with Shire to develop therapeutics for hemophilia, Huntingtons' disease and other monogenic diseases and, in non-therapeutic applications of its technology, has strategic partnerships with Dow AgroSciences and Sigma-Aldrich Corporation.

Visit Website
View all Sponsors & Exhibitors
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman